ReviewFrontiers in neurology2026
Tau abnormalities and microglial remodeling in glaucoma: potential links to phagocytosis-related injury.
Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glaucoma is a progressive optic neuropathy characterized by retinal ganglion cell degeneration and optic nerve damage. Increasing evidence indicates that glaucomatous injury is not limited to the retina, but may also involve downstream visual structures and neuroimmune responses. Tau abnormalities and microglial remodeling have each been reported in glaucoma models and human glaucomatous tissues, yet they are usually discussed as separate pathological findings. Whether these processes are connected, and how they might contribute to synaptic, dendritic, and axonal injury, remains insufficiently defined. Review focus: This review examines current evidence for tau dysregulation and glaucoma-associated microglial remodeling in glaucoma. Experimental studies support retinal tau accumulation, altered phosphorylation, and redistribution from axonal to somatodendritic compartments after intraocular pressure elevation, whereas evidence for oligomeric tau remains limited to a single rat ocular-hypertension study. In parallel, glaucoma-associated microglia show loss of homeostatic signatures and acquisition of neurodegeneration-associated features, including APOE/Galectin-3-related remodeling, complement activation, inflammatory signaling, and phagocytosis-related changes. Evidence from tauopathy research provides several plausible links between tau-related neuronal stress and microglial responses, including NF-κB signaling, TLR4-NLRP3 inflammasome activation, complement-mediated recognition, and glial clearance of tau-altered synaptic or neuronal substrates. However, most of these links have not been directly tested in glaucoma. Aqueous humor biomarkers, including total tau, phosphorylated tau, neurofilament light chain, glial fibrillary acidic protein, APOE, and Galectin-3, may offer clinically accessible readouts of neuronal and glial injury, but they cannot establish temporal order or causality. Conclusion: Available evidence supports tau dysregulation and glaucoma-associated microglial remodeling as relevant but not yet causally linked components of glaucomatous neurodegeneration. A cautious working model is that tau-related neuronal stress may alter dendritic, synaptic, or axonal substrates, while remodeled microglia and complement pathways may influence recognition and clearance of vulnerable structures. Future studies should test these interactions directly by combining tau species-specific analysis, microglial state profiling, engulfment assays, and visual pathway outcomes within the same experimental framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.